Erlotinib and Chemoradiation Followed by Maintenance Erlotinib for Locally Advanced Pancreatic Cancer

Iannitti, David A.; DiPetrillo, T.A.; Akerman, Paul A.; Barnett, John M.; Maia-Acuna, Christine; Cruff, Dennis; Miner, Tom; Martel, Diane; Cioffi, William G.; Remis, M.; Kennedy, T. A.; Safran, Howard

doi:10.1097/01.coc.0000184682.51193.00

Cited by 77 publications

(30 citation statements)

References 19 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a phase III trial for patients with advanced pancreatic cancer, erlotinib plus gemcitabine has shown a statistically significant survival benefit compared with gemcitabine alone (Tang et al, 2006). In another study combining erlotinib with gemcitabine and irradiation for locally advanced unresectable pancreatic cancer, most of the evaluable patients showed disease stabilization (Iannitti et al, 2005). When combined with capecitabine, erlotinib has shown considerable anti-tumor activity and better tumor control in a phase II trial for advanced pancreatic cancer.…”

Section: New Strategies For the Treatment Of Pancreatic Cancers Targementioning

confidence: 99%

Pancreatic cancer: Pathogenesis, prevention and treatment

Sarkar

Banerjee

2007

Toxicology and Applied Pharmacology

103

View full text Add to dashboard Cite

Pancreatic cancer is the fourth leading cause of cancer death in the United States with a very low survival rate of 5 years. To better design new preventive and/or therapeutic strategies for the fight against pancreatic cancer, the knowledge of the pathogenesis of pancreatic cancer at the molecular level is very important. It has been known that the development and the progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways among which the EGFR, Akt, and NF-κB pathways appear to be most relevant. Therefore, the strategies targeting EGFR, Akt, NF-κB, and their downstream signaling could be promising for the prevention and/or treatment of pancreatic cancer. In this brief review, we will summarize the current knowledge regarding the pathogenesis, prevention, and treatment of pancreatic cancer.

show abstract

Section: New Strategies For the Treatment Of Pancreatic Cancers Targementioning

confidence: 99%

Pancreatic cancer: Pathogenesis, prevention and treatment

Sarkar

Banerjee

2007

Toxicology and Applied Pharmacology

103

View full text Add to dashboard Cite

show abstract

“…Erlotinib has been evaluated in two phase I studies using a multimodal chemoradiation approach. One study examined erlotinib plus gemcitabine and paclitaxel plus radiation followed by maintenance with erlotinib and reported a partial response rate of 46 % and median survival time of 14 months (Iannitti et al 2005). These results are supported by the other trial of erlotinib plus gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer (Duffy et al 2008).…”

Section: Pancreatic Adenocarcinomamentioning

confidence: 90%

Erlotinib

Steins¹,

Thomas²,

Geißler³

2014

Recent Results in Cancer Research

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways such as cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of them are important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer and pancreatic cancer with emphasis to the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy and toxicity as well as predictive markers of response are discussed.

show abstract

“…During chemoradiotherapy, at doses of ≥75 mg of erlotinib, dose-limiting toxicities (DLTs) reported were diarrhoea, dehydration, rash and small bowel stricture. The maintenance dose of 150mg was well tolerated [86].…”

Section: Tyrosine Kinase Inhibitorsmentioning

confidence: 95%

Pancreatic cancer: from molecular pathogenesis to targeted therapy

Strimpakos

Saif

Syrigos

2008

Cancer Metastasis Rev

View full text Add to dashboard Cite

Pancreatic cancer is a deadly malignancy with still high mortality and poor survival despite the significant advances in understanding, diagnosis, and access to conventional and novel treatments. Though cytotoxic chemotherapy based on the purine analogue gemcitabine remains the standard approach in adjuvant and palliative setting the need for novel agents aiming at the main pathophysiological abnormalities and molecular pathways involved remains soaring. So far, evidence of clinical benefit, though small, exists only from the addition of the targeted agent erlotinib on the standard gemcitabine chemotherapy. Apart from the popular monoclonal antibodies and small molecules tyrosine kinase inhibitors, other novel compounds being tested in preclinical and clinical studies target mTOR, NF-kappaB, proteasome and histone deacetylase. These new drugs along with gene therapy and immunotherapy, which are also under clinical evaluation, may alter the unfavorable natural course of this disease. In this review we present the main pathophysiological alterations met in pancreatic cancer and the results of the florid preclinical and clinical research with regards to the targeted therapy associated to these abnormalities.

show abstract

Erlotinib and Chemoradiation Followed by Maintenance Erlotinib for Locally Advanced Pancreatic Cancer

Abstract: The maximum tolerated dose of erlotinib with gemcitabine, paclitaxel and concurrent radiation is 50 mg/d for patients with locally advanced pancreatic cancer. Full dose maintenance erlotinib is well tolerated. Promising preliminary activity and overall survival were demonstrated.

Cited by 77 publications

References 19 publications

Pancreatic cancer: Pathogenesis, prevention and treatment

Pancreatic cancer: Pathogenesis, prevention and treatment

Erlotinib

Pancreatic cancer: from molecular pathogenesis to targeted therapy

Contact Info

Product

Resources

About